Moertel Criticizes Janssen Over Levamisole Price, Delivers Final Report On Intergroup Adjuvant Trial
In Brief: Seffrin’s ACS Appointment Is Official; Liotta Selected As NIH; Strategic Plan Meetings
Other ASCO Plenary Papers: Long Awaited Chemotherapy Results
Congress Okays NIH Reauthorization, Allows NCI $472 Mil. More
Gallo Inquiry Complete; NCAB’s AIDS Committee Plans Q&A Session
NCAB Decides To End IGs, Review total Research Support, And Consider P01 Limitation
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Break Through Cancer’s Tyler Jacks: “We’ve created a new operating model for collaborative cancer research.”
- One result, two reactions: GRAIL’s Hall and NCI’s Castle react to negative NHS-Galleri trial outcome
- Vinay Prasad, oncology’s gadfly-turned-CBER-director, will leave FDA (again)
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - As more people are surviving cancer, we must continue funding bold science









